OIA
CTXR icon

Optimum Investment Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Optimum Investment Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed – – 825
2022
Q2 		$0 Hold
2
– – ﹤0.01% 841
2022
Q1 		$0 Buy
+2
New +$79 ﹤0.01% 849

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return

Optimum Investment Advisors's CTXR Position: Q3 2022 in Review

Optimum Investment Advisors sold out of Citius Pharmaceuticals (CTXR) in Q3 2022, closing a stake of 2 shares.

Optimum Investment Advisors first reported a position in CTXR in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 56 funds tracked by Wall St. Rank hold CTXR as of Q3 2022.

  • Optimum Investment Advisors reported no remaining Citius Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Optimum Investment Advisors sold 2 Citius Pharmaceuticals shares in Q3 2022.
  • Optimum Investment Advisors first reported a position in Citius Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • Optimum Investment Advisors's Citius Pharmaceuticals position peaked at $0 in Q2 2022.
  • 56 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2022.

Based on Optimum Investment Advisors's 13F filing for Q3 2022, filed 24 Oct 2022.